Teva Pharmaceuticals to Halt Phase 2 Trial of Neurodegenerative Drug Emrusolmin Over Lack of Efficacy

08:51 AM EST, 11/02/2026 (MT Newswires) -- Teva Pharmaceuticals (TEVA) will halt its phase 2 TOPAS-MSA trial of emrusolmin in adults with multiple system atrophy following an independent committee's recommendation, the company said Monday. The interim analysis showed a low likelihood of the study meeting its primary efficacy endpoint, with no safety concerns identified. Teva will further analyze the study and available open-label extension data, while keeping the broader emrusolmin program under evaluation, it added. Teva Pharmaceuticals shares were down 3% in premarket activity.